ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,424.20
0.05%
Dow Jones
39,806.77
-0.49%
Gold vs US Dollar
2,414.065
-0.51%
Brent Oil
83.065
-0.56%
Bitcoin
70,917.12
-0.74%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Orchard Therapeutics PLC (ORTX)

  7. Orchard Therapeutics PLC (ORTX) News

Orchard Therapeutics (ORTX)

Orchard Therapeutics PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ORTX
DateTimeSourceHeadlineSymbolCompany
07/05/202412:00GlobeNewswire Inc.Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024NASDAQ:ORTXOrchard Therapeutics PLC
03/05/202412:00GlobeNewswire Inc.Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health ListNASDAQ:ORTXOrchard Therapeutics PLC
20/03/202411:00GlobeNewswire Inc.Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic LeukodystrophyNASDAQ:ORTXOrchard Therapeutics PLC
18/03/202419:41GlobeNewswire Inc.Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.NASDAQ:ORTXOrchard Therapeutics PLC
15/02/202402:05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ORTXOrchard Therapeutics PLC
05/02/202419:39Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:ORTXOrchard Therapeutics PLC
05/02/202412:00GlobeNewswire Inc.Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler SyndromeNASDAQ:ORTXOrchard Therapeutics PLC
02/02/202412:00GlobeNewswire Inc.Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposiumNASDAQ:ORTXOrchard Therapeutics PLC
31/01/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ORTXOrchard Therapeutics PLC
31/01/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ORTXOrchard Therapeutics PLC
25/01/202412:00GlobeNewswire Inc.Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to LibmeldyNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202422:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202422:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202422:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202421:41Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202421:39Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202421:37Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202421:35Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202421:34Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202421:30Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202421:28Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202421:25Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202421:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202410:00GlobeNewswire Inc.Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseasesNASDAQ:ORTXOrchard Therapeutics PLC
22/01/202421:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORTXOrchard Therapeutics PLC
19/12/202321:49Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORTXOrchard Therapeutics PLC
11/12/202312:00GlobeNewswire Inc.Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLDNASDAQ:ORTXOrchard Therapeutics PLC
08/12/202321:39Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ORTXOrchard Therapeutics PLC
08/12/202321:37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORTXOrchard Therapeutics PLC
30/11/202321:13Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ORTXOrchard Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:ORTX

Your Recent History

LSE
VAST
Vast Resources
LSE
GLEN
Glencore
LSE
ARCM
Arc Minerals
LSE
VAL
Valirx
LSE
ENET
Ethernity Networks
LSE
PXC
Phoenix Copper
LSE
TEK
Tekcapital
LSE
ULT
Ultrasis
LSE
SCLP
Scancell
LSE
QBT
Quantum Blockchain Techn...
LSE
GKP
Gulf Keystone Petroleum
LSE
IES
Invinity Energy Systems
LSE
BGO
Bango
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved